Vaxcyte, Inc. SEC filings PCVX

Vaxcyte, Inc. has 767 filings in SEC EDGAR's recent list, going back to Jul 24, 2015. Its latest annual report, Form ARS, was filed on Apr 23, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (results of operations). The company's fiscal year ends on December 31.

Vaxcyte, Inc. SEC filings
Form Description Filed Period
10-Q Quarterly report Nov 4, 2026 Sep 30, 2026
10-Q Quarterly report Aug 5, 2026 Jun 30, 2026
10-Q Quarterly report May 6, 2026 Mar 31, 2026
10-Q Quarterly report Nov 4, 2025 Sep 30, 2025
10-Q Quarterly report Aug 6, 2025 Jun 30, 2025
10-Q Quarterly report May 7, 2025 Mar 31, 2025
10-Q Quarterly report Nov 5, 2024 Sep 30, 2024
10-Q Quarterly report Aug 6, 2024 Jun 30, 2024
10-Q Quarterly report May 8, 2024 Mar 31, 2024
10-Q Quarterly report Nov 6, 2023 Sep 30, 2023
10-Q Quarterly report Aug 8, 2023 Jun 30, 2023
10-Q Quarterly report May 8, 2023 Mar 31, 2023
10-Q Quarterly report Nov 7, 2022 Sep 30, 2022
10-Q Quarterly report Aug 8, 2022 Jun 30, 2022
10-Q Quarterly report May 9, 2022 Mar 31, 2022
10-Q Quarterly report Nov 10, 2021 Sep 30, 2021
10-Q Quarterly report Aug 11, 2021 Jun 30, 2021
10-Q Quarterly report May 11, 2021 Mar 31, 2021
10-Q Quarterly report Nov 12, 2020 Sep 30, 2020
10-Q Quarterly report Aug 12, 2020 Jun 30, 2020

Showing 20 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
PCVX (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
San Carlos, CA
SEC filer status
Large accelerated filer
SEC CIK
1649094
Former names
SutroVax, Inc. (until Apr 3, 2020)

Other Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.